Alvotech

Alvotech is a global biopharmaceutical company specializing in the development and manufacturing of biosimilar biologic medicines for patients worldwide. Headquartered in Reykjavik, Iceland, the company operates a vertically integrated model covering cell line development, clinical trials, and commercial fill-and-finish manufacturing. Alvotech focuses on high-demand therapeutic areas, including oncology, immunology, and ophthalmology, offering monoclonal antibody biosimilars that provide cost-effective alternatives to reference biologics. The organization utilizes single-use fermentation technologies in its state-of-the-art facilities powered almost entirely by local geothermal and hydroelectric renewable energy. Through global commercial partnerships, Alvotech expands patient access to critical healthcare solutions across major international pharmaceutical markets in Europe, North America, and Asia. Its robust pipeline features biosimilar candidates targeting prominent biologic therapies such as Entyvio, durvalumab, and emicizumab. Operating advanced R&D and pharmaceutical science facilities across Iceland, Germany, Sweden, Switzerland, the United Kingdom, and the United States, Alvotech ensures strict adherence to FDA and EMA cGMP regulatory standards. The business collaborates with leading regional distributors and healthcare organizations to deliver affordable biologic options without compromising quality or safety.